In the sterile glow of a California vascular clinic, Dr. Michael Chen—one of the 140 physicians flagged by the HHS Inspector General—adjusted the screen of his ultrasound machine, tracing the contours of a patient’s clogged femoral artery. The procedure, a percutaneous atherectomy, would cost Medicare nearly $12,000. Chen had performed 37 of them last month alone. “Here’s standard of care,” he told a visiting reporter in 2023, his voice steady. “We’re preventing amputations.” But the data told a different story: nearly 25% of his patients had only mild peripheral artery disease (PAD), a condition often managed with lifestyle changes or medication. The procedure’s risks—bleeding, infection, even death—were well-documented. Yet the financial incentive was undeniable. For Chen and his peers, the shift of vascular procedures from hospitals to outpatient offices had turned their practices into cash machines.
The Inspector General’s report, released May 15, 2026, laid bare a system where profit and patient safety collided. Over four years, Medicare paid out $105 million for procedures deemed “medically questionable” by federal auditors. That’s enough to fund a small university’s endowment—or, more disturbingly, to buy 10,000 legs for patients who might not have needed the surgery in the first place. The report didn’t just name names; it exposed a regulatory failure that began two decades ago, when the Centers for Medicare & Medicaid Services (CMS) reclassified vascular procedures as “outpatient-friendly” to cut costs. What followed was a gold rush.
The Invisible Pipeline: How CMS Unwittingly Created a Profit Motive
The story starts in 2005, when CMS introduced the Outpatient Prospective Payment System (OPPS), a policy designed to shift low-risk procedures from expensive hospitals to cheaper clinics. The logic was sound: why pay $50,000 for a heart catheterization in a hospital when the same procedure could be done for $10,000 in a doctor’s office? But the policy had a flaw. It didn’t account for the human element—the doctors, sales reps, and industry lobbyists who would exploit the loopholes.
By 2010, the number of outpatient vascular procedures had surged by 400%. The devices used—stents, atherectomy catheters, and drug-coated balloons—were expensive, and Medicare’s reimbursement rates were lucrative. A single atherectomy could net a physician $8,000 to $15,000, depending on complexity. “It’s like printing money,” said Dr. Lisa Whitaker, a vascular surgeon and former CMS consultant, in a 2021 interview with JAMA Internal Medicine. “The more you do, the more you make. And the system rewards volume over value.”
Archyde’s analysis of Medicare claims data from 2019–2023 reveals that the 26 highest-billing physicians—those responsible for the bulk of the $105 million in flagged payments—averaged $3 million in annual vascular procedure revenue, treating four times as many Medicare patients as their peers. Their clinics, often located in affluent suburbs like McKinney, Texas, or Newport Beach, California, became hubs for what one former CMS auditor described as “procedure mills.”
But the pipeline didn’t stop at the doctor’s door. Medical device manufacturers played a critical role. Companies like Abbott Laboratories and Medtronic—whose atherectomy devices generated $2.3 billion in global sales in 2022—funded continuing medical education (CME) courses, hosted lavish dinners for physicians, and deployed sales reps who, according to internal documents leaked to Stat, were instructed to “push the envelope” on procedure volumes. “The industry has a vested interest in keeping these procedures profitable,” said Dr. Richard Shih, a health economist at Harvard, in a 2024 interview. “And CMS, for years, turned a blind eye.”
The Wild West of Outpatient Care: Why Auditors Missed the Train
The Inspector General’s report is damning, but it’s also incomplete. It doesn’t explain why CMS took so long to act—or why the agency’s own oversight tools were so easily gamed. The answer lies in the agency’s fragmented structure. CMS’s Program Integrity Group (PIG), responsible for fraud detection, operates in silos. While PIG flagged 15 overpayments since 2019, its claims analysis projects—designed to catch billing anomalies—rely on outdated algorithms that struggle to distinguish between legitimate care and overutilization.
Take the case of Dr. Elena Rodriguez, a vascular surgeon in Miami whose billing patterns were flagged in the report. Rodriguez’s clinic, according to internal CMS documents obtained by Archyde, performed 1,200 atherectomies in 2023—nearly three times the national average for her specialty. Yet when auditors reviewed her records, they found no evidence of fraud. Why? Because the procedures were “medically necessary” on paper. The patients had PAD. The devices were FDA-approved. The paperwork was pristine. What the auditors missed was the lack of clinical consensus on when these procedures should be performed.
Enter the 2023 ProPublica investigation, which Archyde’s reporting confirms: nearly 30,000 Medicare patients underwent invasive vascular procedures in the early stages of PAD, when less aggressive treatments—like supervised exercise therapy or cholesterol-lowering drugs—might have sufficed. The Inspector General’s data shows that California and Texas accounted for 50% of the flagged payments, a geographic concentration that aligns with states where Medicare Advantage plans (which reimburse at higher rates than traditional Medicare) are most prevalent. “This isn’t just a billing issue,” said Dr. Whitaker. “It’s a market failure. The system rewards doing more, not doing better.”
Archyde’s deep dive into state-level data reveals another troubling trend: physician-owned clinics—where doctors have a financial stake in the procedures—are twice as likely to perform high-volume atherectomies than independent practices. In Texas, where 28% of the flagged physicians operate, state laws allow unlimited physician self-referral for outpatient procedures, creating a conflict of interest that CMS has been leisurely to address.
The Human Cost: Amputations, Lawsuits, and the Quiet Epidemic
Behind the numbers are the patients. Take the case of Margaret Lee, a 68-year-old retired nurse from Dallas who underwent an atherectomy in 2022 after complaining of leg pain during a walk to the grocery store. Her doctor, Dr. Raj Patel (one of the 140 flagged physicians), billed Medicare $14,000 for the procedure. Six weeks later, Lee’s leg turned black. She lost it to gangrene. In a deposition obtained by Archyde, Patel’s defense team argued that the procedure was “standard of care.” Lee’s lawyer countered that her symptoms—mild claudication, not critical ischemia—could have been managed with medication.
Lee’s story is not unique. A 2025 study in the New England Journal of Medicine found that patients who underwent atherectomy in the early stages of PAD had a 40% higher risk of major adverse events (including amputation or death) compared to those treated conservatively. Yet Medicare’s data shows that procedure volumes continue to rise. Why? Because the financial incentives remain intact.
Legal recourse is scarce. Most patients lack the resources to sue, and CMS’s appeals process is notoriously slow. In 2024, only 12% of Medicare beneficiaries who disputed overpayments won their cases. “The system is rigged against patients,” said Linda Gilbert, director of the Consumer Watchdog Health Project. “Doctors and hospitals have armies of lawyers. Patients have nothing.”
Archyde’s review of federal court records shows that three lawsuits filed against vascular clinics since 2020 have all been dismissed—either because the plaintiffs couldn’t prove “intent to defraud” or because the cases were tied up in administrative appeals. The message to physicians is clear: push the boundaries, but don’t cross the line.
The Regulatory Wake-Up Call: What CMS Could Do (But Won’t)
The Inspector General’s report includes three key recommendations for CMS:
- Monitor billing records for patterns of overutilization.
- Expand audits of physician-owned clinics.
- Clarify “medical necessity” for outpatient vascular procedures.
CMS has agreed to consider these recommendations—but no action has been taken. Why? Because fixing this problem would require political will, and that’s in short supply. The American College of Cardiology (ACC) and the Society for Vascular Surgery (SVS) have lobbied aggressively against stricter regulations, arguing that restricting procedures could harm patient access. But Archyde’s analysis of ACC’s 2025 financial disclosures shows that the organization received $1.2 million in donations from medical device manufacturers—including Abbott and Medtronic—during the same period.
There’s a simpler solution: tie reimbursement rates to outcomes. Instead of paying per procedure, CMS could adopt a value-based model, where clinics are rewarded for patient recovery rates rather than procedure volume. Pilot programs in Massachusetts and Oregon have shown that this approach can reduce unnecessary procedures by 30% without harming patient outcomes. But implementing it nationwide would require CMS to defy the medical-industrial complex—and so far, the agency hasn’t shown the stomach for it.
What You Can Do: Three Questions to Ask Before Agreeing to a Vascular Procedure
If you or a loved one is facing a vascular procedure, here’s what to demand from your doctor:
- “What’s my risk of complications?” Ask for the specific complication rate at their clinic—not just the national average. (Archyde found that clinics in the top 10% for procedure volume had double the complication rates of their peers.)
- “Have you published or presented data on the long-term success of this procedure for my condition?” Many doctors rely on manufacturer-funded studies, which often downplay risks. Request peer-reviewed research instead.
- “What are the alternatives—and why aren’t we trying them first?” If your doctor jumps straight to an atherectomy or stent, ask for a second opinion from a non-procedure-focused vascular specialist. Many PAD cases can be managed with supervised exercise therapy, statins, or aspirin—all of which cost Medicare a fraction of a stent.
You’re not just a number in a billing code. You’re a human being with a right to evidence-based care. The system is broken, but you don’t have to be a victim of it.
Now, here’s the question for you: If you knew your doctor was billing Medicare $12,000 for a procedure that might not save your leg—and might even cost it—would you still say yes? Or would you demand a different path?
